United Therapeutics

YTD

ALL

Trade United Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin.

CEO

Martine A. Rothblatt

CEOMartine A. Rothblatt

Employees

1,400

Employees1,400

Headquarters

Silver Spring, Maryland

HeadquartersSilver Spring, Maryland

Founded

1996

Founded1996

Employees

1,400

Employees1,400

UTHR Key Statistics

Market cap

21.37B

Market cap21.37B

Price-Earnings ratio

17.44

Price-Earnings ratio17.44

Dividend yield

—

Dividend yield—

Average volume

533.13K

Average volume533.13K

High today

$505.00

High today$505.00

Low today

$479.71

Low today$479.71

Open price

$495.00

Open price$495.00

Volume

618.56K

Volume618.56K

52 Week high

$609.35

52 Week high$609.35

52 Week low

$375.61

52 Week low$375.61

Stock Snapshot

United Therapeutics(UTHR) stock is priced at $497.97, giving the company a market capitalization of 21.37B. It carries a P/E multiple of 17.44.

On 2026-09-08, United Therapeutics(UTHR) stock traded between a low of $479.71 and a high of $505.00. Shares are currently priced at $497.97, which is +3.8% above the low and -1.4% below the high.

The United Therapeutics(UTHR)'s current trading volume is 618.56K, compared to an average daily volume of 533.13K.

During the past year, United Therapeutics(UTHR) stock moved between $375.61 at its lowest and $609.35 at its peak.

UTHR News

Investing.com 5h

United Therapeutics at Wells Fargo conference: pipeline points to growth - Investing.com

...

TipRanks 10h

United Therapeutics announces accelerated share repurchase agreement

United Therapeutics (UTHR) announced that the company will utilize the remainder of its previously announced $2B share repurchase authorization. To complete the...

TipRanks 6d

United Therapeutics announces FDA accepted sNDA for Tyvaso

United Therapeutics (UTHR) announced that the FDA has accepted the supplemental New Drug Application, or sNDA, for nebulized Tyvaso, or treprostinil, Inhalation...

Analyst ratings

81%

of 16 ratings

Buy

81.3%

Hold

18.8%

Sell

People also own

Based on the portfolios of people who own UTHR. This list is generated using Robinhood data, and it’s not a recommendation.

Sterling Infrastructure

Argan

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.